Introduction
DC are professional antigen-presenting cells with the primary function to initiate and regulate T cell responses. DC are widely distributed in tissues where they form a sentinel network to detect, capture and process antigens. 1 In recent years, it has become evident that DC should be viewed as a system of antigen-presenting cells with diverse and distinct properties, rather than a single or unique cell type. 2, 3 In human blood, there are at least two different DC populations: CD1c + myeloid PBDC and IL-3R + plasmacytoid DC (PDC). Monocytes can differentiate into DC in vitro when cultured in the presence of GM-CSF and IL-4 or IL-13 for 5-7 days. [4] [5] [6] Alternatively, a subset of CD16 + monocytes can transform into DC following migration through an endothelial cell monolayer and ingestion of particulates in the collagen matrix below. 7, 8 Most of our knowledge about DC has been gained from studying MoDC.
However, identification of a physiological counterpart in vivo still remains unresolved.
Therefore, a direct functional comparison of MoDC and physiological DC types is essential to better understand DC biology.
DC can be activated by an array of physiologic stimuli, such as those derived from microbes (e.g. lipopolysaccharide, bacterial DNA containing unmethylated CpG-motifs), activated T cells (e.g. CD40-ligation) or mediators of inflammation (e.g. pro-inflammatory cytokines).
Such stimuli induce DC to undergo a process called 'maturation', which transforms them from cells specialized in antigen capture into cells specialized in activating T cells. 1 Antigen uptake and T cell activation are separate functions requiring the migration of DC from the site of antigen encounter to regional lymphoid tissues. Upon activation, DC upregulate the chemokine receptors CXCR-4 and CCR-7, enabling them to migrate towards gradients of the chemokines CXCL12 (SDF-1 ) and CCL19/CCL21 (MIP-3 /6Ckine), respectively, which is important for lymph node homing. However, it has been demonstrated that chemokine receptor expression is not predictive of the migratory capacity of some DC types. For instance, PGE 2 is an important regulator of migratory function of MoDC. 9, 10 Recently, it has been reported that activation of MoDC by extracellular ATP induces upregulation of CXCR-4
and to a lesser extent CCR-7 and enables them to migrate towards CXCL12 and CCL19, even in the absence of exogenous PGE 2 . 11 Therefore, nucleotides may represent another class of important soluble factors regulating the migratory capacity of DC.
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From Nucleotides, such as ATP, ADP and UTP, can act as extracellular signaling molecules via activation of membrane-bound P2 receptors (P2R) and have been linked to the regulation of immune and inflammatory responses. 12 P2R can be subdivided into P2XR, a family of ligand-gated ion channels, and G-protein-coupled 7-membrane spanning P2YR. 13 MoDC express mRNA for both P2XR and P2YR, including P2X 1 , P2X 2 , P2X 4 , P2X 5 , P2X 7 , P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2Y 11 and P2Y (13) (SP174). [14] [15] [16] [17] [18] In MoDC, nucleotide signaling through P2R has been associated with the upregulation of activation markers and chemokine receptors, cytokine and chemokine secretion, and induction of apoptosis. 11, [14] [15] [16] [17] 19, 20 Pharmacological data point towards the P2Y 11 R mediating maturation of MoDC by ATP. 21 Studies on the cloned P2Y 11 R showed that the ATP-derivatives BzATP, ATP S and dATP are potent agonists, whereas suramin is a competitive antagonist. 22 The P2Y agonists dibutyryl cAMP and 8-bromo-cAMP were purchased from Wako (Tokyo, Japan).
Materials and Methods

Media and Reagents
Monoclonal antibodies and cytokines
Flow cytometric analysis was performed using fluorocrome-conjugated mAb against CD1a, CD1c, CD3, CD14, CD20, CD83, CD86, CD123w, HLA-DR, CXCR-4, CCR-7
(PharMingen/Becton Dickinson, San Jose, CA); BDCA-1 and BDCA-4 (Miltenyi Biotech, Auburn, CA). The cytokines TNF-, IL-4, and IL-3 were ordered from Peprotech, Rocky
Hill, NJ; GM-CSF (40ng/ml) from Schering-Plough, Sydney, Australia; and IFN-2a
(Roferon-A) from Roche Products PTY., Sydney, Australia. Soluble CD40L-trimer (CD40L) was a gift from Immunex (Seattle, WA).
Generation of monocyte-derived DC (MoDC) and isolation of DC types from the peripheral blood
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats from healthy volunteers provided by the Red Cross Blood Bank (Melbourne, Australia). PBMC were prepared by Ficoll-Paque density gradient centrifugation (Amersham Biosciences, Uppsala, Sweden). MoDC were generated as previously described. 9 In short, CD14 + monocytes were positively selected using anti-CD14 miniMACS (Miltenyi Biotech, Auburn, CA) and cultured at a density of 5x10 5 cells/ml in RPMI-10% FCS in the presence of GM-CSF (40ng/ml) and IL-4 (500U/ml (13) SP174. 18 Primers were synthesized by Sigma Genosys. 1µl cDNA was used as template. PCR products were separated on a 1% agarose gel containing ethidium bromide.
Quantitative real time PCR (RT-qPCR)
Gene expression levels were quantitated using ABI Prism 7700 Sequence Detection System 
Cell migration assay
Assays were performed as previously described. 9 Briefly, lower chambers of trans-well plates (8µm pore size for MoDC, 5µm pore size for PBDC and CD1a + dermal DC) (Costar, Corning, NY) were filled with 500µl RPMI/10% FCS with or without the following chemokines: CCL19 (MIP-3 ) (300ng/ml); CCL21 (6Ckine) (100ng/ml); CXCL12 (SDF-1 ) (30ng/ml); CCL3 (MIP-1 ) (50ng/ml) (all from PeproTech). In some experiments, nucleotides were added to the chemokine-containing side of the trans-wells. were incubated with fluo-3 acetoxymethyl ester (fluo-3/AM) (4µg/ml) and Fura Red (Fura 
Statistical analysis
Data are expressed as mean values + SEM. Statistical significance of differences was determined by the paired or unpaired two-tailed Student t test. Differences were considered to be significant for p < 0.05 and are indicated by asterix in the graphs.
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Results
Regulation of migratory function of MoDC differs from physiological DC types
We and others have previously shown that although the expression of the chemokine receptors CXCR-4 and CCR-7 can be induced on MoDC by pro-inflammatory cytokines, intact bacteria or CD40L, receptor expression was not always predictive of efficient migratory function towards CXCL12 and CCL21. Maximal migratory function required MoDC to be exposed to the above stimuli in the presence of PGE 2 .
9,10 Interestingly, CD1c + PBDC and IL-3R + PDC differed from MoDC in this respect. These DC types, which mature spontaneously during in vitro culture, migrated efficiently towards CXCL12 and CCL21 in the absence of exogenous PGE 2 ( Figure 1 ). An alternative inducer of MoDC migration towards CXCL12, and to a lesser extent CCL21, was found to be exposure to extracellular ATP. 11 The data in Figure 1 confirm this finding. Moreover, as was seen with PGE 2 -containing stimuli, the present study found that ATP did not enhance the rapidly acquired migratory function of Representative experiments of at least four different donors are shown (mean + SEM of triplicates).
Gradients of ATP inhibit chemokine-directed migration of MoDC
Since DC will be exposed to a complex array of pro-inflammatory mediators, cytokines, Figure 2D) . A 50% inhibition of migration of CD1a + dermal DC was seen with 50-100µM ATP. In contrast, migration of CD1c + PBDC and IL-3R + PDC was unaffected by the presence of ATP in the chemokine gradient (Figure 2A ). ATP concentrations as high as 500µM were ineffective, ruling out non-specific effects, such as buffer toxicity (data not shown).
Inhibition of migration by ATP is P2R-mediated
To determine whether the inhibitory effect of ATP on DC migration is mediated by P2R, we studied the effect of P2R agonists and antagonists on DC migration. For both MoDC and CD1a + dermal DC, the ranking order of potency of various P2R agonists was ATP S BzATP > dATP > ATP > 2MeSATP ( Figure 3A , B and D). As little as 10µM of either ATP S or BzATP or dATP dramatically inhibited the migration of MoDC ( Figure 3A ). UTP and the degradation products of ATP with activity on purinergic receptors, such as ADP and adenosine, induced no significant inhibition of migration ( Figure 3A and B) . Next, we studied the influence of several P2R antagonists on the ATP-effect. The P2R antagonist suramin completely abrogated ATP-mediated inhibition of MoDC migration (n=8, p<0.01) whilst the antagonist reactive blue 2 (RB-2) was partially effective (n=5, n<0.01) ( Figure 3C ). In contrast, the P2R antagonist PPADS and oxidized ATP were both ineffective. Interestingly, the profile obtained with both P2R agonists and antagonists is characteristic for the cloned P2Y 11 R, as described by Communi et al.
22
For 
Inhibition of MoDC migration by ATP is mediated through phospholipase C
The P2Y 11 R is dually coupled to phosphatidyl inositol/phospholipase C/protein kinase C as well as adenylyl cyclase/cAMP/protein kinase A pathways. 22 To examine whether protein kinase A activation could inhibit the migratory function of MoDC, migratory-type MoDC were exposed to activators of this pathway, such as PGE 2 , forskolin, db-cAMP or 8-bromocAMP, prior to or during the migration assay. As shown in Figure 4A , protein kinase A agonists did not affect DC migration. In contrast, phorbol 12-myristate 13-acetate (PMA), a potent activator of protein kinase C, completely inhibited MoDC migration. Since these findings provide only indirect evidence of a possible mechanism of action for ATP, we examined the influence of these signaling pathways on the ATP-effect using specific 
Human MoDC and physiological DC types express mRNA for the same P2XR and P2YR
Since ATP-mediated inhibition of migration was observed for MoDC and CD1a + dermal DC, but not for CD1c + PBDC or IL-3R + PDC, we speculated that these DC types differ in the expression pattern of their P2R repertoire, especially with respect to P2Y 11 R. Due to the unavailability of mAb against most P2R, including the P2Y 11 R, we analyzed the P2R expression of all four DC types by conventional RT-PCR. Surprisingly, we found similar mRNA expression patterns for P2R, including the P2Y 11 R, in all four DC populations ( Figure   5 ). However, there was donor-to-donor variation as well as semi-quantitative differences in P2R expression between the four DC types. 
Discussion
In the cytosol, ATP is present in a concentration of 5-10mM and in the 100-1000mM range in intracellular compartments of platelets. ATP can be actively released by regulated exocytosis (e.g. by activated platelets, endothelial cells and T cells), by traumatic cell lysis or passive leakage from damaged cells. [27] [28] [29] Under physiological conditions, the concentration of extracellular ATP is regulated by ecto-nucleotidases, such as ecto-ATP/ADPase (CD39), which hydrolyzes ATP and ADP to AMP, a nucleotide with no intrinsic activity on P2R. 30 In inflamed tissues, release of ATP and down regulation of CD39 can cause accumulation of extracellular ATP. 31 ATP signals through P2R and exhibits regulatory effects on immune and inflammatory responses. 12 Since under normal conditions, high concentrations of ATP are restricted to intracellular compartments, the accumulation of extracellular ATP likely reflects tissue damage and may present a "danger-signal" to the immune system. 32 The influence of elevated extracellular ATP levels in vivo have been studied in CD39 -/-mice, which lack the capacity to degrade extracellular ATP. Altered immune responses and defects in DC function indicate that nucleotides likely play an important role in immune responses in vivo. 33 First evidence that these effects could, at least in part, be a result of an impaired migratory function of leukocytes came from the same mice, which displayed a severe defect in cell migration with decreased cellular infiltrates as well as a complete failure of neo-vascularization at sites of tissue injury. 34 The effects of ATP on human DC have been studied using in vitrogenerated MoDC and exposure to high micromolar concentrations of ATP has been linked to maturation, enhanced T cell stimulatory capacity, cytokine production and apoptosis. [14] [15] [16] [17] [19] [20] [21] However, it is now clear that MoDC are not functionally equivalent to their physiological counterparts found in the blood. 9 In the present study, we compared MoDC with three physiological DC populations -CD1a + dermal DC, CD1c + myeloid PBDC and IL-3R + PDCwith respect to the regulation of their migratory function, P2R expression and the influence of ATP on chemokine-directed migration.
Pronounced differences between MoDC, CD1c + PBDC and IL-3R + PDC were observed when studying the regulation of their migratory function. MoDC gained full migratory capacity 24h
after stimulation with PGE 2 -containing stimuli, as previously described. At sites of inflammation or tissue damage, it is likely that DC will be simultaneously exposed to gradients of ATP, chemokines and maturation inducing cytokines, which permeate out of the epicenter of inflammation. We were interested in determining, whether ATP within a chemokine gradient influences DC migration. We found that gradients derived from micromolar concentrations of ATP potently inhibited the migration of MoDC and CD1a + dermal DC. By applying various P2R agonists and antagonists, we demonstrated that the inhibitory effect of ATP on DC migration was P2R-mediated. Strikingly, the ranking order of potency of P2R agonists and antagonists was identical with the pharmacological profile of the cloned P2Y 11 R. 22 Since the human P2Y 11 R signals through phospholipase C/ protein kinase C as well as adenylyl cyclase/protein kinase A, we studied the influence of both signaling pathways on DC migration. We found that ATP-mediated inhibition of MoDC migration was mediated by phospholipase C, since inhibition of phospholipase C with U-73122 abolished the ATP-effect on migration. However, we cannot exclude the possibility that the results maybe due to an unreported effect of U-73122 that potentially disrupts the ATP-gradient thereby abrogating the inhibitory effect of ATP. Interestingly, inhibition of protein kinases A and C were both ineffective in this respect. However, addition of the protein kinase C agonist -flux studies (unpublished data). Monoclonal Abs directed against P2Y 11 R and P2Y 11 R-specific agonists to investigate this are currently unavailable.
Taken together, our data indicate that the physiological consequences of exposure to ATP on DC migration depend on i) the ATP concentration, ii) the type of DC and iii) the maturational stage of the DC (the latter two influencing the P2R repertoire). The proposed working hypothesis is that low concentrations of ATP at the onset of inflammation may initially induce the recruitment of immature tissue-resident DC (e.g. in the dermis) into sites of inflammation or tissue damage as previously reported. 23 Here, chemotaxis is mediated by P2YR that are sensitive to nanomolar concentrations of ATP (or ADP and UTP), such as P2Y 1 R, P2Y 12 R as well P2Y 2 R, P2Y 4 R and P2Y 6 R. 23 However, once in the epicenter of inflammation, the accumulation of ATP will transiently cause an arrest in cell movement. This effect, most likely mediated by the P2Y 11 R, can override the chemotactic effect of nucleotides as well as chemokines. Arrest of migration may serve the purpose of prolonging the DC's capacity to encounter and internalize antigens as well as prolonging exposure to maturation-inducing factors. Eventually, degradation of extracellular ATP and down regulation of P2Y 11 R will allow mature DC to migrate out of these sites of inflammation and towards draining lymph nodes where they can interact with T cells. In contrast, blood DC populations are insensitive to the regulatory effect of ATP on migration and other, yet unidentified factors are likely to regulate their migratory function.
In conclusion, we describe a novel mechanism by which ATP can regulate the trafficking of specific DC populations. Since migration of DC from the site of antigen capture to lymphoid tissue is a prerequisite for the induction and regulation of immune responses, ATP-mediated inhibition of migration could play an important role in inflammatory diseases and cancer.
Pharmacological targeting of the P2Y 11 R may thus represent a new therapeutic strategy to improve the migration of in vitro-generated DC or tissue-resident DC to induce trafficking of antigen from the vaccine site to the draining lymph nodes.
